

H1/Q2 2026 RESULTS

OLIVIER RIGAUD (CEO)
PETER KAZIUS (CFO)

31-Jul-2026

This presentation contains forward-looking statements with respect to Corbion's future performance and position. Such statements are based on current expectations, estimates, and projections of Corbion and information currently available to the company. Corbion cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. Also, for a variety of reasons including many factors outside the control of Corbion, there can be no guarantee that any proposed strategic initiatives will be completed within the expected time frame or at all. Nor can there be any guarantee that Corbion will be able to realize any of the potential strategic benefits, synergies, or opportunities, or any guarantee that shareholders will achieve any particular level of return in relation thereto. Corbion has no obligation to update the statements contained in this presentation, unless required by law.

More details on Corbion's H1 2026 financial performance can be found in the H1 2026 press release. A more comprehensive discussion of the risk factors affecting Corbion's business is available in the company's Annual Report 2025.

This presentation to investors includes alternative performance measures (APMs), and information that is presented in accordance with IFRS as issued by the International Accounting Standards Board ('IFRS figures').

Corbion results H1/Q2 2026

Olivier Rigaud

CEO

- **Business performance**
- **Outlook**

Peter Kazius

CFO

- **Financial performance**

H1 2026 Highlights

- **Organic sales growth of +2.1% to € 631.1 million (Q2: +8.5% to € 337.4 million)**
  - Volume/mix +4.0%
  - Pricing -1.9%
- **Adjusted EBITDA € 88.8 million (Q2: € 51.0 million)**
- **Health & Nutrition: Double-digit-% volume/mix growth in Nutrition and Biomaterials; negative growth in Pharma driven by phasing of sales orders. Strong sales and EBITDA margin outlook for H2, with expected pricing tailwinds**
- **Functional Ingredients & Solutions: Positive volume/mix growth (+4.2%); EBITDA margins increased sequentially, with more upside expected in H2**
- **Free Cash Flow € -4.0 million**
- **FY 2026 outlook adjusted**

Volume/mix

+4.0% (H1)
+10.7% (Q2)

Adj EBITDA margin

14.1% (H1)
15.1% (Q2)

Free Cash Flow

€ -4.0m (H1)
€ 11.7m (Q2)

Functional Ingredients & Solutions

Q2 accelerates as margin recovery begins

Business environment

- Sales grew +3.6% in H1 and +8.4% in Q2 on higher volumes and improved sales
- Markets stayed resilient; stable pricing
- Middle East conflict impacting input costs

Growth initiatives

- New customer wins in natural food-preservation
- New listeria regulation in Europe supporting growth

Efficiency measures

- H2 actions aim to offset cost pressure from the situation in the Middle East
- Cost mitigation actions as anticipated

Food wins keep momentum positive

+8.4%

Q2 sales growth

Volume/mix grew across all three businesses; EBITDA margin improved +250 bps vs Q1

Corbion

Health & Nutrition

Tight omega-3 supply gives Nutrition a stronger H2

Business environment

- Double-digit-% volume/mix growth in Nutrition and Biomaterials
- Supply shortages + resilient aquaculture demand support H2 pricing in Nutrition
- Q2 sales improved strongly as customer phasing normalized

Growth initiatives

- Aquaculture, pet and human nutrition remained strong
- KAS astaxanthin milestones and a new DHA-rich algae patent extend the platform

Efficiency measures

- Debottlenecking and yield gains increase algal-fermentation output

Supply pressure remains the catalyst

H2

Phasing benefits continue

Contracts and pipeline point to stronger volume/mix and pricing

Corbion

Fish oil dynamics: Tight supply meets resilient aquaculture demand

Supply risk map



Supply remains fragile

- Peru reduced quotas constrain availability
- Nordic / Scandinavian quotas limit alternative fish oil supply

Demand anchored by salmon farming

- Aquaculture accounts for >70% of fish oil use; salmonids are the largest species group
- Algae-derived DHA supports salmon health, growth, feed conversion and filet quality

Commercial implication

- Supply gap may widen in 2026, supporting H2/2026 pricing and contract negotiations

Source: IFFO market updates/statistics;

Corbion

Financial performance

Peter Kazius

CFO

H1 Sales and Adjusted EBITDA development





Corbion

Profit and Loss

€ million	YTD 2026	YTD 2025	%	Q2 2026	Q2 2025	%
Net Sales	631.1	645.6	-2.2%	337.4	315.9	6.8%
Adjusted EBITDA	**88.8**	**106.6**	**-16.7%**	**51.0**	**52.2**	**-2.3%**
Adjusted Depreciation & Amortization	-42.9	-42.5	0.9%	-21.2	-22.1	-4.1%
Adjustments	-3.8	-0.6		-2.4	-0.6	
EBIT	**42.1**	**63.5**	**-33.7%**	**27.4**	**29.5**	**-7.1%**
Financial income/expenses	-5.0	-10.7		-3.5	-5.1	
Result joint ventures/assoc.	-	-1.1		-	-0.4	
Taxes	-7.3	-9.3		-5.9	-3.9	
Result after tax	**29.8**	**42.4**	**-29.7%**	**18.0**	**20.1**	**-10.4%**

Corbion

Functional Ingredients & Solutions

H1 Organic Sales growth of +3.6% (Q2: +8.4%)

- **Volume/mix +4.2% (Q2: +8.7%)**
  - **Food** - growth in natural preservation, particularly in bakery, petfood, and seafood end-markets
  - **Biochemicals** – volume/mix growth in several end markets, both in H1 and Q2
  - **Lactic Acid to PLA joint venture** – volume growth following growth in the joint venture
- **Pricing -0.6% (Q2: -0.3%)** driven by Lactic Acid to the joint venture

EBITDA margins declined to 10.3%, -160 bps (Q2: 11.5% , -20 bps)

- EBITDA margin declined in H1 versus last year, mainly due to product mix effects
- Strong sequential margin improvement (+250 bps)

€ million	H1 2026	H1 2025		Q2 2026	Q2 2025
Sales	492.7	497.5		256.7	240.5
Organic growth	+3.6%	+1.9%		+8.4%	-1.8%
Adjusted EBITDA	50.7	59.1		29.4	28.1
Adjusted EBITDA margin (%)	10.3%	11.9%		11.5%	11.7%



Strong Q2 growth driven by volume/mix



Q2 margins improved sequentially

Corbion

Health & Nutrition

H1 Organic Sales growth of -3.3% (Q2: +8.7%)

- **Volume/mix +2.8% (Q2: +16.9%)**
  - **Nutrition** – double-digit-% volume/mix growth in H1, following strongly Q2 with as-expected phasing
  - **Biomedical Polymers** – double-digit-% volume/mix growth, with growth in all end-markets
  - **Pharma** broadly in line with expectations, although negative growth impacted by phasing effects at key customers
- **Pricing -6.1% (Q2: -8.2%)** compared with the higher prices in H1 2025 driven by relatively greater sales on short-term contracts
  - strong positive pricing impact expected in H2 vs H1

H1 Adjusted EBITDA margin 27.5%, -460 bps (Q2: 26.8%, -520 bps) driven by lower pricing in **Nutrition** and product mix (lower sales in **Pharma)**

- Q2 margin declined sequentially due to product-mix effects, with proportionately higher **Nutrition** sales; margins anticipated to improve strongly in H2

€ million	H1 2026	H1 2025		Q2 2026	Q2 2025
Sales	138.4	148.1		80.7	75.4
Organic growth	-3.3%	+6.8%		+8.7%	-0.6%
Adjusted EBITDA	38.1	47.5		21.6	24.1
Adjusted EBITDA margin (%)	27.5%	32.1%		26.8%	32.0%

Organic sales growth
Health & Nutrition

Q2
+8.7%



Phasing from Q1

Adjusted EBITDA margin
Health & Nutrition

Q2
26.8%



Temporarily reduced margins in Q2

Corbion

TotalEnergies Corbion joint venture

H1 sales growth +21.6% (Q2: +44.7%)

- Strong demand for PLA plastics, particularly in Asia

H1 Adjusted EBITDA margin 7.5%, -220 bps vs LY (Q2: 9.2%, -250 bps)

- Adjusted EBITDA margin higher vs Q1

JV sale process continuing as planned

- Corbion continues to work closely with prospective buyers, JV partner, and advisors

€ million*	H1 2026	H1 2025		Q2 2026	Q2 2025
Sales	79.0	69.4		42.3	30.0
Organic growth	+21.6%	+5.6%		+44.7%	-9.3%
Adjusted EBITDA	5.9	6.7		3.9	3.5
Adjusted EBITDA margin (%)	7.5%	9.7%		9.2%	11.7%

*Results on 100% basis. Corbion owns 50% of TotalEnergies Corbion joint venture



4th consecutive quarter of sales growth



Margins growing on higher sales

Corbion

Investments, working capital, and Free Cash Flow

CapEx Program
(€ million)



- **Disciplined CapEx program to support growth**
  - Maintenance €17 million
  - Expansion €10m in Food (natural preservation), Biomaterials, and Nutrition
  - CapEx in line with last-year H1 level

Operating Working Capital
(% of sales)



- **Operating working capital up €36.9 million**
  - Temporary increase mainly driven by accounts receivable due to sales phasing; overdues are stable

Free Cash Flow
(€ million) – excluding divestments



- **FCF in line with seasonal trends**
  - Result in line with outlook; H1 impacted by accounts receivable due to timing of sales

Corbion

Outlook

Corbion

FY 2026 outlook adjusted

Organic sales growth:	+3-6%	[Maintained]
Adjusted EBITDA margin:	>16%	[Previously ~17%]
Free Cash Flow*:	€ 85-90 million	[Maintained]
CapEx spend 2026-2028:	~6% of sales	[Maintained]

* Free Cash Flow = Cash Flow from operating activities -/- Cash Flow from investment activities (excluding acquisitions/disposals)

Corbion

Annex

Sales and Adjusted EBITDA: H1/Q2 2026

€ million	H1 2026	H1 2025	H1 Growth		Q2 2026	Q2 2025	Q2 Growth
Sales							
- Functional Ingredients & Solutions	492.7	497.5	-1.0%		256.7	240.5	+6.7%
- Health & Nutrition	138.4	148.1	-6.5%		80.7	75.4	+7.0%
Total Net Sales	**631.1**	645.6	**-2.2%**		**337.4**	**315.9**	+6.8%
Adjusted EBITDA							
- Functional Ingredients & Solutions	50.7	59.1	-14.2%		29.4	28.1	+4.6%
- Health & Nutrition	38.1	47.5	-19.8%		21.6	24.1	-10.4%
Total Adjusted EBITDA	**88.8**	106.6	**-16.7%**		**51.0**	**52.2**	-2.3%
Adjusted EBITDA margin							
- Functional Ingredients & Solutions	10.3%	11.9%	-160 bps		11.5%	11.7%	-20 bps
- Health & Nutrition	27.5%	32.1%	-460 bps		26.8%	32.0%	-520 bps
Total Adjusted EBITDA margin	**14.1%**	**16.5%**	**-240 bps**		**15.1%**	**16.5%**	**-140 bps**

Corbion

Sales growth per segment in H1/Q2 2026

Sales growth	Vol./Mix	Price	Organic		FX	Acq./ Div.	Total growth
H1 2026 vs H1 2025							
Total	**+4.0%**	**-1.9%**	**+2.1%**		**-4.3%**	**0.0%**	**-2.2%**
- Functional Ingredients & Solutions	+4.2%	-0.6%	+3.6%		-4.6%	0.0%	-1.0%
- Health & Nutrition	+2.8%	-6.1%	-3.3%		-3.2%	0.0%	-6.5%
Q2 2026 vs Q2 2025							
Total	**+10.7%**	**-2.2%**	**+8.5%**		**-1.7%**	**0.0%**	**+6.8%**
- Functional Ingredients & Solutions	+8.7%	-0.3%	+8.4%		-1.7%	0.0%	+6.7%
- Health & Nutrition	+16.9%	-8.2%	+8.7%		-1.7%	0.0%	+7.0%

Corbion

Net debt bridge H1 2026



- **Net debt position H1 2026: € 481.6 million** (incl. subordinated loans).
- **Net debt/EBITDA** 2.6x
  - Covenant Net Debt to covenant EBITDA: 2.0x
  - Positive Free Cash Flow in Q2, negative for H1

 *CapEx: € 27.6m and movement CapEx creditors: € 5.1m

Corbion

Corbion

Investor relations

alex.sokolowski@corbion.com

www.corbion.com

+31 20 590 6341

Business performance

Olivier Rigaud

CEO

Corbion